• Search
  • Login
  • Register
Menu
  • BJMO
  • Home
  • News
  • CongressUpdate
  • Specials
  • Links
All
  • All
  • BJMO articles
  • Blog articles
  • Specials
Forgot Password? Not a member yet? Register here
News > Pharma News

Category

All
  • Pharma News
  • Health of Tomorrow
  • Opinion
  • Art Corner
  • Fundraising
  • Prevention
  • Science
  • Clinical Practice
  • Corona
  • Cancer trials
  • Healthy Living
  • Medical Research
  • Art on View
  • Viewpoints
  • Therapy
  • Health Innovation
  • Podcasts
  • Editor's pick
  • Publishing News
  • Special
  • BSMO Meeting 2021
  • Covid-19
  • EADO 2021

Pharma News

Tucatinib (Tukysa®) reimbursed as of October 2023

Read more
subscribe Latest issue All issues Newsletters
Index latest issue
  • The Belgian Virtual Tumourbank: Residual tumour samples with high quality data
  • Rethinking the reimbursement of innovative medicines in oncology: Looking beyond overall survival
  • Individualising radiation therapy decisions in breast cancer patients based on tumour-infiltrating lymphocytes and genomic biomarkers
  • Early-onset cancers: Incidence trends in Belgium, 2004–2020
  • Improving dysphagia care in head and neck cancer patients treated with radiotherapy
  • Journal Scan
  • New oncology reimbursements in Belgium
(sponsored)
Pharma News

NEW ONCOLOGY REIMBURSEMENT IN BELGIUM: TRASTUZUMAB DERUXTECAN (ENHERTU®)

Read more
(sponsored)
Pharma News

NEW ONCOLOGY REIMBURSEMENT IN BELGIUM: OLAPARIB (LYNPARZA®)

Read more
Pharma News

Osimertinib plus chemotherapy prolongs PFS in EGFR-mutated NSCLC patients

Read more
Pharma News

Novel therapy for ESR1-mutated advanced or metastatic breast cancer approved by FDA

Read more
Pharma News

Pembrolizumab plus chemotherapy delays disease progression in endometrial carcinoma

Read more
Pharma News

NALIRIFOX regimen improves OS and PFS in patients with metastatic PDAC

Read more
Pharma News

FDA approves first gene therapy for patients with high-risk bladder cancer

Read more
(sponsored)
Pharma News

ADDING ABEMACICLIB TO FIRST LINE ENDOCRINE THERAPY RESULTS IN A CLINICALLY RELEVANT SURVIVAL B...

Read more
1 2 3 4 5 Next
Top

Join our newsletter

  • This field is for validation purposes and should be left unchanged.
  • About BJMO
  • Ads & sponsoring
  • Vacancies
  • Disclaimer
  • Privacy
  • Contact

BJMO is published by Ariez International BV, Westzijde 22, 1506 EE Zaandam, The Netherlands

© BJMO 2023